Romain‐David Seban

Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors

Romain‐David Seban, Laura Mezquita, Arnaud Berenbaum et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2019 · 133 citations

Medicine, Nuclear Medicine, Oncology +17

Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics

Romain‐David Seban, John S. Nemer, Aurélien Marabelle et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2019 · 129 citations

Medicine, Cancer Biology, Oncology +16

¹⁸F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti–Programmed Death 1 Immune Checkpoint Inhibitor

Laurent Dercle, Romain‐David Seban, Julien Lazarovici et al. · Journal of Nuclear Medicine · 2017 · 116 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0

Egesta Lopci, Rodney J. Hicks, Antonia Dimitrakopoulou‐Strauss et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2022 · 105 citations · Full text

Medicine, Nuclear Medicine, Radiology +17

Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4

Romain‐David Seban, Antoine Moya‐Plana, Lara Antonios et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 81 citations

Medicine, Immunology, Oncology +17